Related Experiment Videos
Prostaglandin E2 affects both insulin secretion and peripheral insulin sensitivity
A M Borissova1, S Zaharieva, T S Tankova
1National Institute of Endocrinology and Gerontology, Bulgarian Medical Academy, Sofia.
Diabete & Metabolisme
|May 1, 1991
Summary
Prostaglandin E2 (PGE2) significantly decreases plasma C-peptide levels and impairs peripheral insulin effectiveness in healthy volunteers. This suggests PGE2 plays a role in regulating insulin secretion and sensitivity.
Area of Science:
- Endocrinology
- Metabolic Research
- Pharmacology
Background:
- Prostaglandin E2 (PGE2) is a lipid mediator with diverse physiological roles.
- Its precise effects on insulin secretion and peripheral insulin sensitivity require further elucidation.
Purpose of the Study:
- To investigate the impact of PGE2 on plasma C-peptide (CP) levels.
- To assess the effect of PGE2 on peripheral insulin effectiveness in healthy individuals.
Main Methods:
- Plasma CP levels were measured in 14 volunteers during a 3-hour PGE2 infusion versus saline control.
- Peripheral insulin sensitivity was evaluated using the euglycemic hyperinsulinemic clamp technique in two groups: saline (A) and PGE2 during the third hour (B).
Main Results:
- PGE2 infusion led to a significant decrease in plasma CP levels at 15 and 30 minutes (p < 0.05).
- Group A showed a 14.2% increase in glucose infusion rate (GIR) in the third hour compared to the second.
- Group B exhibited no significant change in GIR between the second and third hours, indicating reduced insulin effectiveness (F = 5.68, p < 0.01).
Conclusions:
- PGE2 administration transiently reduces plasma C-peptide levels.
- PGE2 impairs peripheral insulin sensitivity, suggesting a role in glucose homeostasis regulation.